all report title image
  • Published On : Jun 2022
  • Code : CMI158
  • Industry : Biotechnology
  • Pages : 156
  • Formats :

Next Generation Sequencing (NGS) is a high-throughput DNA sequencing technology that separates billions or millions of DNA strands and sequence in parallel, yielding more output and reducing the need for fragment-cloning methods (Sanger sequencing of genomes). However, read lengths for NGS are shorter than Sanger due to the signal to noise ratio, which increases with read length. NGS allows simultaneous screening of mutations in large number of genes. For example, a patient with symptoms of Leigh syndrome can perform exome sequencing to find candidate gene variants. Furthermore, it is used for analysis and for interpreting sequenced data, analyzing specific gene associated with the patient’s clinical condition

The global next generation sequencing market is estimated to be valued at US$ 42.958 million in 2022 and is expected to exhibit a CAGR of 4.3% during the forecast period (2022-2030).

Figure 1.Global Next Generation Sequencing Market Share (%), by Application, 2022

Next Generation Sequencing  | Coherent Market Insights

Rising demand for early detection of cancer and infectious diseases are expected to drive growth of the next generation sequencing market

The chances of successful treatment increase when cancer and infectious diseases are detected at the early stage. One of the major factors that drive growth of the next generation sequencing market is the rising prevalence of cancer and other infectious diseases such as tuberculosis, meningococcal disease, etc. For instance, according to the data provided by World Health Organization (WHO) in February 2022, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.

CMI table icon

Next Generation Sequencing Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 42.958 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 4.3% 2030 Value Projection: US$ 57.71 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Technology: Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Re-sequencing, Others
  • By Application: Drug Discovery, Personalized Medicine and Genetic Screening, Disease Diagnosis, Agriculture and Animal Research, Others
  • By End User: Hospital, Research Centers, Pharma and Biotech Firms, Others 
Companies covered:

Thermo Fisher Scientific Inc., Agilent Technologies, Inc, bioMérieux SA, F. Hoffmann-La Roche Ltd , QIAGEN, Illumina, Inc., Oxford Nanopore Technologies plc., BGI, PerkinElmer Genomics, and Pierian

Growth Drivers:
  • Rising demand for early detection of cancer and infectious diseases
  • Increasing advancements in next generation sequencing procedures
Restraints & Challenges:
  • Storage and management issue of enormous data generated by next generation sequencing and its interpretation

Figure 2.Global Next Generation Sequencing Market Share (%), by Region, 2022

Next Generation Sequencing  | Coherent Market Insights

Increasing advancements in next generation sequencing procedures are expected to drive the market growth during the forecast period.

Demand for DNA testing is increasing, due to advancements in next generation sequencing instruments and technologies, faster results and cost effectives of the process as compared to genotyping based DNA microarray. For instance, in January 2022, a new ultra-rapid genome sequencing approach developed by Stanford Medicine scientists and their collaborators was used to diagnose rare genetic diseases in an average of eight hours. Genome sequencing allows scientists to see a patient’s complete DNA makeup, which contains information about everything from eye color to inherited diseases. Genome sequencing is vital for diagnosing patients with diseases rooted in their DNA

Global Next Generation Sequencing– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, vaccines and medical devices, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, are facing problems with regards to the transportation of products from one place to another

However, the COVID-19 pandemic had a positive impact on the global next generation sequencing market, owing to the increased research and development activities by the key players for utilizing next generation sequencing techniques for the diagnosis of COVID-19 infections. For instance, in June 2020, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Illumina, Inc., a global company that develops innovative array-based solutions for DNA, RNA, and protein analysis, for the first COVID-19 diagnostic test utilizing next generation sequence technology. The FDA authorized the Illumina COVIDSeq Test for the qualitative detection of SARS-CoV-2 RNA from respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider

Global Next Generation Sequencing: Key Developments

In June 6, 2022, PerkinElmer, Inc., a global corporation focused in the business areas of diagnostics, life science research, food, environmental and industrial testing, announced the launch of the research use only (RUO) BioQule NGS System , an automated benchtop solution for next-generation sequencing (NGS) library preparation of up to eight samples. By incorporating automated thermocycling, integrated quality control through optical quantification and robust liquid handling technology into a single device, the BioQule NGS System enables researchers to produce high quality NGS libraries that yield reliable, reproducible results in a variety of applications requiring genomic analysis

In May, 2022, NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced a seamless, cloud-based workflow that improves the spatial data analysis experience of customers using Illumina NextSeq 1000 and NextSeq 2000 sequencing systems and the GeoMx Digital Spatial Profiler. The spatial analysis of whole transcriptomes combined with proteome analytes can now be simplified using this integrated, push-button run planning tool.

Global Next Generation Sequencing: Restraint

The major factors that hinder growth of the global next generation sequencing market include the storage and management issue of enormous data generated by next generation sequencing and its interpretation. Nevertheless, in spite of tremendous advancements to broaden NGS applications from research to clinic, NGS still presents enormous challenges in terms of data storage, processing, quality control management and interpretation, which slow the translation from the bench-top to the bed-side

Key Players

Major players operating in the global next generation sequencing market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc, bioMérieux SA, F. Hoffmann-La Roche Ltd , QIAGEN, Illumina, Inc., Oxford Nanopore Technologies plc., BGI, PerkinElmer Genomics, and Pierian

Next Generation Sequencing (NGS) is a powerful, flexible, and indispensable biological tool that is used in several areas of biological study. NGS technologies help in generating genome-wide sequence data in a couple of days. These technologies are highly parallelized allowing to sequence thousands to millions of molecules at the same time. The main advantage of these platforms is determination of the sequenced data from amplified single DNA fragments, avoiding the need for cloning of DNA fragments.

NGS has large number of applications, enabling rapid technological advances across several fields in biological science. The technology has enabled researchers to gain significant knowledge in public health studies and epidemiology, to sequence viruses and bacteria and help detect causes that may contribute to virulence. Furthermore, in gene expression research, next generation sequencing of RNA replace microarray analysis, allowing researchers to see RNA expression sequence. This RNA sequencing can provide information on entire transcriptome in one analysis, irrespective of any previous knowledge of genetic sequence.

Market Dynamics

The increasing adoption of inorganic strategies such as agreements and partnerships among the key players in the market to advance comprehensive genomic profiling using next generation sequencing is expected to drive the market growth over the forecast period. For instance, in January 2021, Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced a strategic collaboration with Illumina, Inc., a global company that develops innovative array-based solutions for DNA, RNA, and protein analysis, for Illumina to create a kit-based version of the myChoice companion diagnostic (CDx) test for international markets. The agreement between Myriad Genetics, Inc., and Illumina, Inc., combines companion diagnostics and next-generation sequencing to advance comprehensive genomic profiling of tumor samples and drive improved outcomes in oncology

Key features of the study:

  • This report provides in-depth analysis of the global next generation sequencing market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global next generation sequencing market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Agilent Technologies, Inc, bioMérieux SA, F. Hoffmann-La Roche Ltd , QIAGEN, Illumina, Inc., Oxford Nanopore Technologies plc., BGI, PerkinElmer Genomics, and Pierian
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global next generation sequencing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial nalysts1
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global next generation sequencing market

Detailed Segmentation:

  • Global Next Generation Sequencing, By Technology:
    • Whole Genome Sequencing
    • Whole Exome Sequencing
    • RNA Sequencing
    • Targeted Re-sequencing
    • Others
  • Global Next Generation Sequencing, By Application:
    • Drug Discovery
    • Personalized Medicine and Genetic Screening
    • Disease Diagnosis
    • Agriculture and Animal Research
    • Others
  • Global Next Generation Sequencing, By End User:
    • Hospital
    • Research Centers
    • Pharma and Biotech Firms
    • Others
  • Global Next Generation Sequencing, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Thermo Fisher Scientific Inc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Agilent Technologies, Inc
    • bioMérieux SA
    • Hoffmann-La Roche Ltd
    • QIAGEN
    • Illumina, Inc.
    • Oxford Nanopore Technologies plc.
    • BGI
    • PerkinElmer Genomics
    • Pierian

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global next generation sequencing market size is estimated to be valued at US$ 42.958 million in 2022 and is expected to exhibit a CAGR of 4.3% between 2022 and 2030.
Factors such as rising demand for early detection of cancer and infectious diseases and increasing advancements in next generation sequencing procedures are expected to drive the market growth.
Whole Genome Sequencing is the leading technology segment in the market.
The major factor hampering growth of the market include storage and management issue of enormous data generated by next generation sequencing and its interpretation
Major players operating in the market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc, bioMérieux SA, F. Hoffmann-La Roche Ltd , QIAGEN, Illumina, Inc., Oxford Nanopore Technologies plc., BGI, PerkinElmer Genomics, and Pierian

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo